INDBInternet News Database 2.5 Updated 1 min ago · 393 sources Show or hide images Light or dark

FDA Approves Durvalumab With Enfortumab Vedotin for MIBC

Save Like Comments Compare coverage

Summary

With the approval, there's a rival to perioperative pembrolizumab with enfortumab vedotin for patients with cisplatin-ineligible muscle-invasive bladder cancer.

Description from Medscape.

Who is covering this

  1. Medscape Center Factuality: Mostly factual US
    FDA Approves Durvalumab With Enfortumab Vedotin for MIBC

    With the approval, there's a rival to perioperative pembrolizumab with enfortumab vedotin for patients with cisplatin-ineligible muscle-invasive bladder cancer.

Comments

Comments need JavaScript.